PVLA Latest Headlines

Palvella Therapeutics Strengthens Board with Renowned Rare Disease Expert—A Strategic Move for Pipeline Expansion

Market Chameleon (Mon, 13-Apr 8:01 AM)

Palvella Therapeutics Adds Independent Dermatology Expert to Board

at www.tipranks.com (Mon, 13-Apr 8:02 AM)

Palvella’s $200 Million Upsized Offering Draws Spotlight on Rare Disease Pipeline

Market Chameleon (Thu, 26-Feb 11:32 AM)

Palvella's $200M Upsized Public Offering Fuels Rare Disease Pipeline Expansion

Market Chameleon (Thu, 26-Feb 7:41 AM)

PVLA Options Activity Signals Anticipation Ahead of Phase 3 SELVA Trial Results—Is Volatility Justified?

Market Chameleon (Tue, 24-Feb 11:58 AM)

Palvella’s QTORIN Rapamycin Delivers Breakthrough Results in Phase 3 SELVA Study for Rare Vascular Skin Disease

Market Chameleon (Tue, 24-Feb 7:05 AM)